Cargando…
Site-Specific Considerations on Engineered T Cells for Malignant Gliomas
Immunotherapy has revolutionized cancer treatment. Despite the recent advances in immunotherapeutic approaches for several tumor entities, limited response has been observed in malignant gliomas, including glioblastoma (GBM). Conversely, one of the emerging immunotherapeutic modalities is chimeric a...
Autores principales: | Elmadany, Nirmeen, Alhalabi, Obada T., Platten, Michael, Bunse, Lukas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312945/ https://www.ncbi.nlm.nih.gov/pubmed/35885047 http://dx.doi.org/10.3390/biomedicines10071738 |
Ejemplares similares
-
Genetically Modified Cellular Therapies for Malignant Gliomas
por: Kilian, Michael, et al.
Publicado: (2021) -
Clinical and Translational Advances in Glioma Immunotherapy
por: Bunse, Lukas, et al.
Publicado: (2022) -
Dysfunctional dendritic cells limit antigen-specific T cell response in glioma
por: Friedrich, Mirco, et al.
Publicado: (2022) -
K27M-mutant histone-3 as a novel target for glioma immunotherapy
por: Ochs, Katharina, et al.
Publicado: (2017) -
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cells
por: Lu, Kevin Hai-Ning, et al.
Publicado: (2022)